EAA was assessed using various epigenetic clocks to compare samples harboring protective variants for diseases such as AD and atherosclerosis against control samples and those harboring the APOE4 risk allele known to predispose individuals to early-onset AD. This evidence concerns the gene APOE and Alzheimer disease.